257 related articles for article (PubMed ID: 36036061)
1. VHL tumor suppressor as a novel potential candidate biomarker in papillary thyroid carcinoma.
Todorović L; Stanojević B
Biomol Biomed; 2023 Feb; 23(1):26-36. PubMed ID: 36036061
[TBL] [Abstract][Full Text] [Related]
2. Low VHL mRNA expression is associated with more aggressive tumor features of papillary thyroid carcinoma.
Stanojevic B; Saenko V; Todorovic L; Petrovic N; Nikolic D; Zivaljevic V; Paunovic I; Nakashima M; Yamashita S; Dzodic R
PLoS One; 2014; 9(12):e114511. PubMed ID: 25490036
[TBL] [Abstract][Full Text] [Related]
3. Deregulated expression of VHL mRNA variants in papillary thyroid cancer.
Baldini E; Tuccilli C; Arlot-Bonnemains Y; Chesnel F; Sorrenti S; De Vito C; Catania A; D'Armiento E; Antonelli A; Fallahi P; Watutantrige-Fernando S; Tartaglia F; Barollo S; Mian C; Bononi M; Arceri S; Mascagni D; Vergine M; Pironi D; Monti M; Filippini A; Ulisse S
Mol Cell Endocrinol; 2017 Mar; 443():121-127. PubMed ID: 28089820
[TBL] [Abstract][Full Text] [Related]
4. Expression of VHL tumor suppressor mRNA and miR-92a in papillary thyroid carcinoma and their correlation with clinical and pathological parameters.
Todorović L; Stanojević B; Mandušić V; Petrović N; Živaljević V; Paunović I; Diklić A; Saenko V; Yamashita S
Med Oncol; 2018 Jan; 35(2):17. PubMed ID: 29340905
[TBL] [Abstract][Full Text] [Related]
5. miRNA-21 promotes cell proliferation and invasion via VHL/PI3K/AKT in papillary thyroid carcinoma.
Zang C; Sun J; Liu W; Chu C; Jiang L; Ge R
Hum Cell; 2019 Oct; 32(4):428-436. PubMed ID: 31161410
[TBL] [Abstract][Full Text] [Related]
6. miR-1301-3p suppresses tumor growth by downregulating PCNA in thyroid papillary cancer.
Qiao DH; He XM; Yang H; Zhou Y; Deng X; Cheng L; Zhou XY
Am J Otolaryngol; 2021; 42(2):102920. PubMed ID: 33454555
[TBL] [Abstract][Full Text] [Related]
7. MicroRNA-146b: A Novel Biomarker and Therapeutic Target for Human Papillary Thyroid Cancer.
Chou CK; Liu RT; Kang HY
Int J Mol Sci; 2017 Mar; 18(3):. PubMed ID: 28294980
[TBL] [Abstract][Full Text] [Related]
8. Circulating levels of PTEN and KLLN in papillary thyroid carcinoma: can they be considered as novel diagnostic biomarkers?
Razavi SA; Modarressi MH; Yaghmaei P; Tavangar SM; Hedayati M
Endocrine; 2017 Sep; 57(3):428-435. PubMed ID: 28755140
[TBL] [Abstract][Full Text] [Related]
9. Epigenetic inactivation of the RASSF1A 3p21.3 tumor suppressor gene in both clear cell and papillary renal cell carcinoma.
Morrissey C; Martinez A; Zatyka M; Agathanggelou A; Honorio S; Astuti D; Morgan NV; Moch H; Richards FM; Kishida T; Yao M; Schraml P; Latif F; Maher ER
Cancer Res; 2001 Oct; 61(19):7277-81. PubMed ID: 11585766
[TBL] [Abstract][Full Text] [Related]
10. Case Report: A New Entity: Multiple Differentiated Variant of Papillary Thyroid Carcinoma With Advanced Clinical Behavior.
Yang J; Gong R; Ma Y; Gao J; Li Z; Zhu J; Gong Y
Front Endocrinol (Lausanne); 2021; 12():654638. PubMed ID: 33897621
[TBL] [Abstract][Full Text] [Related]
11. Network-based meta-analysis in the identification of biomarkers for papillary thyroid cancer.
Zhao H; Li H
Gene; 2018 Jun; 661():160-168. PubMed ID: 29625265
[TBL] [Abstract][Full Text] [Related]
12. DKK3 is a potential tumor suppressor gene in papillary thyroid carcinoma.
Yin DT; Wu W; Li M; Wang QE; Li H; Wang Y; Tang Y; Xing M
Endocr Relat Cancer; 2013 Aug; 20(4):507-14. PubMed ID: 23702469
[TBL] [Abstract][Full Text] [Related]
13. Update on the cytologic features of papillary thyroid carcinoma variants.
Pusztaszeri M; Auger M
Diagn Cytopathol; 2017 Aug; 45(8):714-730. PubMed ID: 28262004
[TBL] [Abstract][Full Text] [Related]
14. A comparative study of nuclear 8-hydroxyguanosine expression in Autoimmune Thyroid Diseases and Papillary Thyroid Carcinoma and its relationship with p53, Bcl-2 and Ki-67 cancer related proteins.
Mseddi M; Ben Mansour R; Gouiia N; Mnif F; Bousselaa R; Abid M; Boudaouara T; Attia H; Lassoued S
Adv Med Sci; 2017 Mar; 62(1):45-51. PubMed ID: 28187375
[TBL] [Abstract][Full Text] [Related]
15. Serum microRNAs as biomarkers for the diagnosis of papillary thyroid carcinoma: a meta-analysis.
Chen Y; Dong B; Huang L; Huang H
Bosn J Basic Med Sci; 2022 Oct; 22(6):862-871. PubMed ID: 35678022
[TBL] [Abstract][Full Text] [Related]
16. Prognostic utility of BRAF mutation in papillary thyroid cancer.
Xing M
Mol Cell Endocrinol; 2010 May; 321(1):86-93. PubMed ID: 19883729
[TBL] [Abstract][Full Text] [Related]
17. BRAF-activated LncRNA functions as a tumor suppressor in papillary thyroid cancer.
Liao T; Qu N; Shi RL; Guo K; Ma B; Cao YM; Xiang J; Lu ZW; Zhu YX; Li DS; Ji QH
Oncotarget; 2017 Jan; 8(1):238-247. PubMed ID: 27462868
[TBL] [Abstract][Full Text] [Related]
18. Inactivation of the von Hippel-Lindau (VHL) tumour suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: evidence for a VHL-independent pathway in clear cell renal tumourigenesis.
Clifford SC; Prowse AH; Affara NA; Buys CH; Maher ER
Genes Chromosomes Cancer; 1998 Jul; 22(3):200-9. PubMed ID: 9624531
[TBL] [Abstract][Full Text] [Related]
19. Identification of immunohistochemical biomarkers for papillary thyroid carcinoma using gene expression profiling.
Murphy KM; Chen F; Clark DP
Hum Pathol; 2008 Mar; 39(3):420-6. PubMed ID: 18261626
[TBL] [Abstract][Full Text] [Related]
20. Mapping the Molecular Basis and Markers of Papillary Thyroid Carcinoma Progression and Metastasis Using Global Transcriptome and microRNA Profiling.
Akyay OZ; Gov E; Kenar H; Arga KY; Selek A; Tarkun İ; Canturk Z; Cetinarslan B; Gurbuz Y; Sahin B
OMICS; 2020 Mar; 24(3):148-159. PubMed ID: 32073999
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]